SAN DIEGO, Dec. 22 /PRNewswire-FirstCall/ -- Volcano Corporation, a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, reacted positively to the new guidelines for treating coronary disease and heart attacks using percutaneous coronary intervention (PCI), a procedure that treats narrowed blood vessels. Based on the strength of the latest clinical data supporting the usage of Fractional Flow Reserve (FFR), the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society for Cardiovascular Angiography and Interventions (SCAI) elevated the level of evidence for FFR in their guidelines from Level B to Level A, the highest level possible. FFR, a Volcano therapy guidance metric, is determined by using a small pressure wire that is threaded into a coronary artery, and measures the range of pressure across a blockage. The guidelines suggest that FFR can be useful to evaluate intermediate blockages in coronary arteries, determine which lesions will benefit from stenting, and which should be treated with medical therapy alone.